EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces that it will be sponsoring dry eye educational programs and offering special promotions on its Avenova®-branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month.
“Dry eye can be attributed to many factors such as exposure to air pollution and indoor heating and cooling, wearing contact lenses and even staring for too long at computer or smartphone screens,” said Justin Hall, NovaBay CEO. “Over the years we have consistently heard from patients and eyecare professionals alike that managing chronic dry eye can be a challenge. Recognizing that a single approach may not be sufficient to gain and sustain relief from the symptoms of dry eye, NovaBay now offers a full line of best-in-class products under the Avenova brand.
“Throughout July we will be reaching customers and eyecare professionals through advertising, social media, email and direct mail campaigns, and tapping into the expertise of our Optometry and Ophthalmology Advisory Boards and other influencers to raise awareness about dry eye and offer solutions to manage this condition,” he added.
Customers ordering on Avenova.com will receive a 20% discount plus free shipping on the full line of Avenova-branded products, including additional savings for those using the ‘subscribe and save’ function. This promotion allows customers to replenish their Avenova supplies during the summer months and provides special pricing to encourage customers to try additional Avenova products.
Eyecare professionals are invited to participate in the Woo University’s online course “Eyelid Hygiene From Office Education and Product Dispensing to Increasing Patient Compliance at Home” on Thursday, July 13, 2023 from 5:30-6:30 p.m. Pacific time. The COPE-accredited, CE-credit course is being sponsored by Avenova and will be moderated by Jennifer Stewart, OD with featured speaker Elise Kramer, OD. This course aims to educate practitioners how to increase compliance with lid hygiene for patients by offering revenue products in their office and/or ensuring patients have access to recommended products once they leave the office. The course will also discuss the importance of eyelid health for contact lens patients and present studies showing discomfort as the leader of contact lens dropout. Registration is available here.
NovaBay offers best-in-class Avenova-branded products for each step of the standard dry-eye treatment regimen, including Avenova spray, the No. 1 doctor-recommended lid and lash cleanser, lubricating eye drops for instant relief, a warm eye compress to soothe, an antioxidant-rich dietary supplement with omega-3 oils and the i-Chek to monitor eyelid health.
About NovaBay Pharmaceuticals, Inc.:
NovaBay Pharmaceuticals, Inc. develops and sells scientifically created and clinically proven eyecare and skincare products. NovaBay’s leading product, Avenova® Antimicrobial Lid & Lash Solution, is often prescribed by eyecare professionals for blepharitis and dry-eye disease and is also available directly to eyecare consumers through online distribution channels such as Amazon. DERMAdoctor® offers more than 30 dermatologist-developed skincare products through the DERMAdoctor website, well-known traditional and digital beauty retailers, and international distributors. NovaBay also manufactures and sells effective, yet gentle and non-irritating wound care products. The PhaseOne® brand is distributed through commercial partners in the U.S. for professional use only, and the NeutroPhase® brand is distributed in China by Pioneer Pharma (Hong Kong) Company Ltd.
NovaBay Pharmaceuticals Forward-Looking Statements
Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current partnerships, marketing efforts, and any future revenue that may result from such partnerships and related marketing initiatives, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.